Related Experiment Video
Updated: Oct 3, 2026
A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
Published on: December 4, 2018
Analysis of the CHK2 gene in lymphoid malignancies
S Tavor1, S Takeuchi, K Tsukasaki
1Division of Hematology/Oncology, Cedars-Sinai Research Institute, UCLA School of Medicine, 8700 Beverly Blvd, D-5068, Los Angeles, CA 90048, USA. tavorsigal@yahoo.com
Abstract:
The CHK2 gene encodes a protein kinase that is important for the regulation of cell cycle arrest after DNA damage. CHK2 acts downstream of ataxia teleangiecstasia mutated (ATM), modulates the function of p53 and may help mediate cell cycle arrest at G2/M by phosphorylation of Cdc25C. Recently, the human homolog of the checkpoint kinase Cds1 (CHK2) has been suggested to be a tumor suppressor gene. Heterozygous germline mutations have been reported in Li-Fraumeni syndrome (LFS), a highly penetrant familial cancer phenotype, and in sporadic colon cancer. LFS is associated with the development of lymphoid malignancies, especially childhood ALL. Therefore, we analyzed the DNA from 143 lymphoid malignancies to determine whether they had mutations of the CHK2 gene. The 14 exons of CHK2 were studied by polymerase chain reaction-single strand conformational polymorphism (PCR-SSCP) and sequencing of aberrantly migrating bands. One missense mutation changing serine to phenylalanine (codon 428) in an evolutionarily highly conserved domain was found in a non-Hodgkin's aggressive lymphoma. Another point mutation in the non-coding region was identified in one of adult T-cell leukemias (ATL) samples. This result suggests that mutation of the CHK2 gene may rarely be involved in the development of selected lymphomas.
Insights
Mutations in the CHK2 gene, crucial for DNA damage response and cell cycle regulation, were investigated in lymphoid malignancies. Rare CHK2 mutations were identified, suggesting a limited role in the development of certain lymphomas.
Area of Science:
- Molecular Biology
- Genetics
- Oncology
Background:
- The CHK2 gene encodes a protein kinase vital for DNA damage response and cell cycle regulation.
- CHK2 functions downstream of ATM, modulates p53, and aids G2/M cell cycle arrest via Cdc25C phosphorylation.
- CHK2 is implicated as a tumor suppressor, with mutations found in Li-Fraumeni syndrome and sporadic colon cancer.
Purpose of the Study:
- To investigate the frequency and type of CHK2 gene mutations in 143 lymphoid malignancies.
- To determine if CHK2 gene mutations contribute to the development of lymphomas.
Main Methods:
- Analysis of DNA from 143 lymphoid malignancy samples.
- PCR-single strand conformational polymorphism (PCR-SSCP) and sequencing of the 14 exons of the CHK2 gene.
Main Results:
- One missense mutation (Ser428Phe) in a conserved domain was identified in an aggressive non-Hodgkin's lymphoma.
- A point mutation in a non-coding region was found in one adult T-cell leukemia (ATL) sample.
- These findings indicate rare CHK2 mutations in specific lymphoma types.
Conclusions:
- Mutations in the CHK2 gene are infrequently associated with the development of selected lymphoid malignancies.
- Further research may elucidate the precise role of CHK2 in lymphomagenesis.
Related Concept Videos
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...